FDA plans to immediately withdraw or start to wind down 44 COVID-19-related guidances once the public health emergency ends on May 11, including policies related to drug compounding and distribution of drug samples during the PHE, the agency announced Friday (March 10) . The agency also identified 24 guidances it will keep in place beyond the PHE expiration, including those that lay out expectations for the development and licensure of COVID-19 vaccines, explain how FDA conducts remote facility inspections, and...